Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
Authors
Keywords
-
Journal
PLoS One
Volume 12, Issue 5, Pages e0176503
Publisher
Public Library of Science (PLoS)
Online
2017-05-19
DOI
10.1371/journal.pone.0176503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013
- (2016) Jeffrey D Stanaway et al. LANCET
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
- (2016) Jagpreet Chhatwal et al. PHARMACOECONOMICS
- Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
- (2016) Swathi Iyengar et al. PLOS MEDICINE
- The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection
- (2015) Benjamin P. Linas et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
- (2015) Mehdi Najafzadeh et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
- (2015) Jagpreet Chhatwal et al. ANNALS OF INTERNAL MEDICINE
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
- (2013) Nihar Shah et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States
- (2013) Jagpreet Chhatwal et al. VALUE IN HEALTH
- Chronic hepatitis C virus (HCV) disease burden and cost in the United States
- (2012) Homie Razavi et al. HEPATOLOGY
- Trends in Organ Donation and Transplantation in the United States, 1999-2008
- (2010) R. A. Wolfe et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population
- (2010) Keith L. Davis et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis
- (2010) Ana-Carolina Cardoso et al. JOURNAL OF HEPATOLOGY
- Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
- (2008) Hla-Hla Thein et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started